Retifanlimab

Retifanlimab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetProgrammed cell death protein 1 (PD-1)
Clinical data
Trade namesZynyz
Other namesAEX-1188, INCMGA-00012, MGA-012, retifanlimab-dlwr
AHFS/Drugs.comZynyz
MedlinePlusa623017
License data
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC6456H9934N1702O2032S46
Molar mass145381.13 g·mol−1

Retifanlimab, sold under the brand name Zynyz, is an anti-cancer medication used for the treatment of Merkel cell carcinoma.[1] Retifanlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.[1]

It was approved for medical use in the United States in March 2023.[1][2][3][4][5]

  1. ^ a b c d "Zynyz- retifanlimab-dlwr injection". DailyMed. 22 March 2023. Archived from the original on 1 July 2023. Retrieved 20 November 2023.
  2. ^ "FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma". U.S. Food and Drug Administration (FDA). 22 March 2023. Archived from the original on 23 March 2023. Retrieved 22 March 2023. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ^ "Incyte Announces FDA Approval of Zynyz (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)" (Press release). Incyte. 22 March 2023. Archived from the original on 23 March 2023. Retrieved 22 March 2023 – via Business Wire.
  4. ^ "MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of Zynyz (retifanlimab-dlwr)" (Press release). MacroGenics. 22 March 2023. Archived from the original on 23 March 2023. Retrieved 22 March 2023 – via GlobeNewswire.
  5. ^ Kang C (June 2023). "Retifanlimab: First Approval". Drugs. 83 (8): 731–737. doi:10.1007/s40265-023-01884-7. PMID 37184754. S2CID 258687035.